Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Fish oil has been used effectively in the treatment of cardiovascular disease via triglyceride reduction and inflammation modulation. This study aimed to assess the effects of fish oil on patients with nonalcoholic fatty liver disease (NAFLD) associated with hyperlipidemia. Eighty participants with NAFLD associated with hyperlipidemia were randomly assigned to consume fish oil (n=40, 4 g/d) or corn oil capsules (n=40, 4 g/d) for 3 months in a double-blind, randomized clinical trial. Blood levels of lipids, glucose and insulin, liver enzymes, kidney parameters and cytokines at baseline and the end of the study were measured. Seventy people finished the trial. Plasma concentrations of eicosapentaenoic acid and docosahexaenoic acid significantly increased in the fish oil group after intervention. After adjustment for age, gender and BMI, fish oil significantly decreased fasting serum concentrations of total cholesterol, triglyceride, apolipoprotein B and glucose (by (mean±SD) 0.49±0.43 mmol/L, 0.58±0.89 mmol/L, 0.28±0.33 g/L and 0.76±0.56 mmol/L, respectively, P<0.05), as well as alanine aminotransferase and γ-glutamyl transpeptidase levels (by (median (interquartile)) 9.0(0.5, 21.5) and 7.0(2.2, 20.0) IU/L, respectively, P<0.05), significantly increased serum adiponectin levels (by 1.29±0.62 μg/mL, P<0.001), and reduced serum levels of tumor necrosis factor α, leukotrienes B4, fibroblast growth factor 21 (FGF21), cytokeratin 18 fragment M30 and prostaglandin E2 (by 1.70±1.18 pg/mL, 0.59±0.28 ng/mL, 121±31 pg/mL, 83±60 IU/L and 10.9±2.3 pg/mL, respectively, P<0.001). Corn oil had no effect except for increasing serum creatinine concentrations by 7.7±8.9 μmol/L (P=0.008). The effects of fish oil on lipids, glucose and γ-glutamyl transpeptidase were positively correlated with the reductions of serum FGF21 and prostaglandin E2 concentrations after adjustment for age, gender and BMI (r = 0.275 to 0.360 and 0.261 to 0.375, respectively, P<0.05). In conclusion, our findings suggest that fish oil can benefit metabolic abnormalities associated with NAFLD treatment. TRIAL REGISTRATION: ChiCTR-TRC-12002380.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Self-citationObesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830
Lin, Z., Tian, H., Lam, K. S. L., Lin, S., Hoo, R. C. L., Konishi, M., Itoh, N., Wang, Y., Bornstein, S. R., Xu, A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.005 · Cited by 691 · cited 1×
“Previous animal studies found that FGF21 once intravenous infused or daily FGF21 intraperitoneal injection for 12 weeks induced an increase of adiponectin in mice [23, 37, 38].”
BackgroundIncreased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez–Chantar, M. L., & Maratos–Flier, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.054 · Cited by 607
Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Parker, H. M., Johnson, N. A., Burdon, C. A., Cohn, J. S., O’Connor, H. T., & George, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.018 · Cited by 569
Chavez, A. O., Molina-Carrion, M., Abdul-Ghani, M. A., Folli, F., DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-0684 · Cited by 390
Mraz, M., Bartlova, M., Lacinova, Z., Michalsky, D., Kasalicky, M., Haluzikova, D., Matoulek, M., Dostalova, I., Humenanska, V., & Haluzik, M. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03502.x · Cited by 279 · cited 1×
“adiponetin levels were negatively associated with serum FGF21 levels in both obese and T2DM patients [39].”
BackgroundFish Oil for the Treatment of Cardiovascular Disease
Weitz, D., Weintraub, H., Fisher, E., & Schwartzbard, A. Z. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181ea0de0 · Cited by 138 · cited 2×
“Previous studies have shown that fish oil or LC-ω3 intervention effectively reduces triglyceride levels and improves anti-inflammation functions [8].”
Background
Research works printed but not linked: 30
- Y Yilmaz, 2010, Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease, Eur J Clin Invest, 40, 887, 10.1111/j.1365-2362.2010.02338.x · DOI · Paper page
- H Li, 2010, Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride, J Hepatol, 53, 934, 10.1016/j.jhep.2010.05.018 · DOI · Paper page
- H Li, 2013, High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China, J Hepatol, 58, 557, 10.1016/j.jhep.2012.10.029 · DOI
- C Giannini, 2013, Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage, J Clin Endocrinol Metab, 98, 2993, 10.1210/jc.2013-1250 · DOI · Paper page
- AE Feldstein, 2009, Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study, Hepatology, 50, 1072, 10.1002/hep.23050 · DOI · Paper page
- A Guleria, 2013, Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease, Trop Gastroenterol, 34, 74, 10.7869/tg.2012.101 · DOI
- H Shapiro, 2011, The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease, Clin Nutr, 30, 6, 10.1016/j.clnu.2010.06.001 · DOI
- V Nobili, 2013, Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children, Nutr Metab Cardiovasc Dis, 23, 1066, 10.1016/j.numecd.2012.10.010 · DOI
- V Nobili, 2011, Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial, Arch Dis Child, 96, 350, 10.1136/adc.2010.192401 · DOI · Paper page
- 2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 · DOI · Paper page
- A Masood, 2005, A simplified and efficient method for the analysis of fatty acid methyl esters suitable for large clinical studies, J Lipid Res, 46, 2299, 10.1194/jlr.D500022-JLR200 · DOI · Paper page
- Y Qin, 2014, Daidzein supplementation decreases serum triglyceride and uric acid concentrations in hypercholesterolemic adults with the effect on triglycerides being greater in those with the GA compared with the GG genotype of ESR-beta RsaI, J Nutr, 144, 49, 10.3945/jn.113.182725 · DOI
- J Liu, 2015, The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy, Metabolism, 64, 380, 10.1016/j.metabol.2014.11.009 · DOI
- M Yang, 2011, Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus, PLoS One, 6, e26359, 10.1371/journal.pone.0026359 · DOI
- K Li, 2009, Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus, Eur J Endocrinol, 161, 391, 10.1530/EJE-09-0335 · DOI · Paper page
- A Kharitonenkov, 2007, The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21, Endocrinology, 148, 774, 10.1210/en.2006-1168 · DOI · Paper page
- J Villarroya, 2014, Fibroblast growth factor-21 and the beneficial effects of long-chain n-3 polyunsaturated fatty acids, Lipids, 49, 1081, 10.1007/s11745-014-3948-x · DOI
- N Siriwardhana, 2012, Health benefits of n-3 polyunsaturated fatty acids: eicosapentaenoic acid and docosahexaenoic acid, Adv Food Nutr Res, 65, 211, 10.1016/B978-0-12-416003-3.00013-5 · DOI · Paper page
- AD von Frankenberg, 2014, Effect of dietary lipids on circulating adiponectin: a systematic review with meta-analysis of randomised controlled trials, Br J Nutr, 112, 1235, 10.1017/S0007114514002013 · DOI · Paper page
- B Gray, 2013, Omega-3 fatty acids: a review of the effects on adiponectin and leptin and potential implications for obesity management, Eur J Clin Nutr, 67, 1234, 10.1038/ejcn.2013.197 · DOI
- F Guebre-Egziabher, 2013, Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients, Nutrition, 29, 730, 10.1016/j.nut.2012.10.011 · DOI
- A De Rosa, 2013, Adiponectin oligomers as potential indicators of adipose tissue improvement in obese subjects, Eur J Endocrinol, 169, 37, 10.1530/EJE-12-1039 · DOI
- J Salas-Salvado, 2006, Subcutaneous adipose tissue cytokine production is not responsible for the restoration of systemic inflammation markers during weight loss, Int J Obes (Lond), 30, 1714, 10.1038/sj.ijo.0803348 · DOI
- A Gammelmark, 2012, Low-dose fish oil supplementation increases serum adiponectin without affecting inflammatory markers in overweight subjects, Nutr Res, 32, 15, 10.1016/j.nutres.2011.12.007 · DOI
- N Bender, 2014, Fish or n3-PUFA intake and body composition: a systematic review and meta-analysis, Obes Rev, 15, 657, 10.1111/obr.12189 · DOI · Paper page
- WL Holland, 2013, An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice, Cell Metab, 17, 790, 10.1016/j.cmet.2013.03.019 · DOI · Paper page
- Z Lin, 2015, Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice, Circulation, 131, 1861, 10.1161/CIRCULATIONAHA.115.015308 · DOI · Paper page
- K Eto, 2010, Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes, Diabetes Res Clin Pract, 89, 52, 10.1016/j.diabres.2010.03.019 · DOI
- A Bisgaard, 2014, Significant gender difference in serum levels of fibroblast growth factor 21 in Danish children and adolescents, Int J Pediatr Endocrinol, 2014, 7, 10.1186/1687-9856-2014-7 · DOI
- CY Wong, 2010, Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus, Diabet Med, 27, 54, 10.1111/j.1464-5491.2009.02869.x · DOI · Paper page
Cited by
Omega-3 fatty acids in obesity and metabolic syndrome: A mechanistic update
Albracht-Schulte, K., Kalupahana, N. S., Ramalingam, L., Wang, S., Rahman, S. M., Robert-McComb, J., & Moustaid-Moussa, N. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.02.012 · Cited by 355
“Omega-3 PUFAs attenuate HF-diet-induced increases in FGF21 [139] with associated reductions in hyperglycemia, hypertriglyceridemia and plasma insulin levels [140,141].”
BackgroundYang, J., Fernández-Galilea, M., Martínez-Fernández, L., González-Muniesa, P., Pérez-Chávez, A., Martínez, J. A., & Moreno-Aliaga, M. J. (2019) · Nutrients · doi:10.3390/nu11040872 · Cited by 292
Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142
Wang, T., Zhang, X., Zhou, N., Shen, Y., Li, B., Chen, B. E., & Li, X. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029512 · Cited by 73
Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis
Komolafe, O., Buzzetti, E., Linden, A., Best, L. M., Madden, A. M., Roberts, D., Chase, T. J., Fritche, D., Freeman, S. C., Cooper, N. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013157.pub2 · Cited by 21
Metadata
- Authors
- Qin, Y., Zhou, Y., Chen, S.-H., Zhao, X.-L., Ran, L., Zeng, X.-L., Wu, Y., Chen, J.-L., Kang, C., Shu, F.-R., Zhang, Q.-Y., & Mi, M.-T.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-07-30
- Volume
- 10
- Issue
- 7
- Pages
- e0133496
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1929380714
- Cited by
- 101
- References
- 12
- FWCI
- 8.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1371/journal.pone.0133496
- The paper
- Qin, Y., Zhou, Y., Chen, S.-H., Zhao, X.-L., Ran, L., Zeng, X.-L., Wu, Y., Chen, J.-L., Kang, C., Shu, F.-R., Zhang, Q.-Y., & Mi, M.-T. (2015). Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0133496
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.